Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer

被引：0
|
作者：
Kang, S. [1 ]
Lee, S. H. [2 ]
Lee, H. J. [3 ]
Jeong, H. [4 ]
Jeong, J-H. [2 ]
Kim, J. E. [2 ]
Ahn, J-H. [2 ]
Jung, K. H. [2 ]
Kim, H. H. [5 ]
Lee, S. [6 ]
Lee, J.
Kim, S-B. [2 ]
机构：
[1] Chungnam Natl Univ Hosp, Hemato Oncol, Daejeon, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Oncol, Seoul, South Korea
[3] Univ Ulsan, Pathol, Asan Med Ctr, Coll Med, Seoul, South Korea
[4] Univ Ulsan, Dept Internal Med, Asan Med Ctr, Coll Med, Seoul, South Korea
[5] Univ Ulsan, Dept Radiol, Asan Med Ctr, Seoul, South Korea
[6] Univ Ulsan, Surg, Asan Med Ctr, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
305P
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [41] Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer.
    Gandhi, Shipra
    Catalfamo, Kayla
    Attwood, Kristopher
    Kapoor, Ankita
    Jatwani, Karan
    Roy, Arya Mariam
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Evaluation of HER2 scoring algorithms for identification of HER2-low breast cancer
    Costache, S.
    Nagy, A.
    Billingham, K.
    Haynes, H.
    Chefani, A.
    Thomas, T.
    Wedden, S.
    D'Arrigo, C.
    VIRCHOWS ARCHIV, 2020, 477 : S222 - S223
  • [43] HER2-Low Breast Cancer Can Be Visualized by HER2 PET Reply
    Seban, Romain-David
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (11) : 1841 - 1842
  • [44] Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
    Ma, Youzhao
    Zhu, Mingda
    Zhang, Jingyang
    Lv, Minhao
    Chen, Xiuchun
    Liu, Zhenzhen
    CANCER RESEARCH AND TREATMENT, 2023, 55 (04): : 1210 - 1221
  • [45] Efficacy of first line CDK4/6 inhibitors in HER2-low vs HER2-zero, hormone receptor positive, HER2 negative metastatic breast cancer
    Sanchez-Bayona, Rodrigo
    Teran, Santiago
    De Torre, Ana Sanchez
    Alva, Manuel
    Lema, Laura
    Manso, Luis
    Toledo, Estefania
    Roncero, Ana Maria
    Merino, Cristina
    Martinez, Mario
    Parrilla, Lucia
    Ciruelos, Eva
    Tolosa, Pablo
    CANCER RESEARCH, 2022, 82 (04)
  • [46] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
  • [47] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wang, Wei
    Zhu, Tingting
    Chen, Hao
    Yao, Yongzhong
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (06): : 1673 - 1681
  • [48] The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
    Wei Wang
    Tingting Zhu
    Hao Chen
    Yongzhong Yao
    Clinical and Translational Oncology, 2023, 25 : 1673 - 1681
  • [49] Neoadjuvant chemotherapy with HER2 inhibitors for breast cancer
    Fujita, Tetsuji
    LANCET, 2012, 379 (9833): : 2237 - 2237
  • [50] Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer
    Shi, Wenjie
    Wan, Xinyu
    He, Jinzhi
    Wang, Ye
    Zhang, Weiwei
    Xu, Yinggang
    Huang, Xiaofeng
    Chen, Rui
    Xu, Lu
    Zha, Xiaoming
    Wang, Jue
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (04) : 384 - 393
12345